explore -WSS

explore

author：explore 2025-09-07 17:19:48 - browse：951

Susan Tousi is leaving Illumina to become CEO of cancer liquid-biopsy startup Delfi. Nasdaq

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June.

Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference, while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs. Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and build on the initial launch of its lung cancer screening test last fall, the latest example of growing interest in the vast and increasingly competitive liquid biopsy market.

Illumina’s own ambitions to enter this space recently came undone after a prolonged battle with U.S. and European regulators finally pushed the company to announce last month that it would divest Grail, which it had acquired for $8 billion two years earlier. Bas Verhoef, Illumina’s head of region for Europe, will serve as interim chief commercial officer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Researchers use wearables data and AI to predict preterm birth risk

leisure time

WSS

FDA advisers vote against ALS treatment from BrainStorm

Paxlovid should be available without a positive Covid test

STAT Virtual Event: JPM Recap, Live!

How the Dana

Nonprofit, backed by Microsoft, to certify AI tools in health care

After a drawn out lobbying fight, ARPA

knowledge

explore

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Gene therapy denied for Afghan refugee whose father aided U.S.

Virginia high school admissions case could be legal follow

JPM pitch from hospitals? Revenue streams outside of patient care

BioMarin wins approval for gene therapy to treat hemophilia A

Study suggests new cause of Down syndrome: cells linked to aging

Supreme Court strikes down use of affirmative action

Gene therapy denied for Afghan refugee whose father aided U.S.

Alkermes shareholders re

Health tech startups drop sharply from 2021 highs

explore

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Mindstrong's demise and the future of mental health care

Medicare Advantage overpayments discussion gets experts fired up

Medicare Advantage overpayments discussion gets experts fired up

Allen Institute goes after foundational questions, CEO Costa says

Hospital chaplains balance Covid safety with patients’ spiritual needs

hotspot

leisure time

Wikipedia

entertainment